Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD
Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices
An investigative agent in the Novartis asthma pipeline could give biologics a run for their money.
Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.
The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug
Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices
Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema
In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?
Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project
Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena
A loaded hemophilia A drug market is an indication patients in and around it are well-served, but that hasn't stopped contenders such as Roche's emicizumab.
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer
Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue
Type 2 diabetes has been hogging health headlines lately — and for good reason. But the incidence of type 1 diabetes is also on the rise.
Merck said the FDA accepted its submission of a Keytruda/chemotherapy combo drug and granted it Priority Review.
Sanofi, Regeneron denied bid to overturn Amgen win in patent case; Abbott to close St. Jude deal; Gilead hires SVP of hematology and oncology
GSK's two-drug combo for HIV has positive Phase-III results; the FDA approves glucose system that doesn't use finger pricking; Rite Aid to sell stores
BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA
How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy
Here's a look at 100 experimental therapies in late-stage clinical trials.
Lilly's experimental Alzheimer's drug fails in another trial; two more patients die during trial for Juno's CAR-T therapy; NEJM launches platform in China
Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials
Novartis to delay clinical trials of contact lens for diabetes patients; the ADA calls for hearings on insulin pricing; Vice launches healthcare channel
Keytruda is the first immuno-oncology drug approved to treat first-line lung cancer.
The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.
Opdivo fails in lung cancer trial; hedge fund sues Theranos; Takeda and Crescendo partner to develop humabody-based therapies
A race has emerged in a new disease space estimated to be worth billions of dollars.
Drugmakers routinely pay ghostwriters to write industry-funded research articles; Horizon to buy Raptor for $800 million; WellDoc partners with J&J
Novartis to fold its cell and gene therapy business; Novo Nordisk CEO to retire; the FDA issues a safety warning for opioids taken with anti-anxiety drugs
- Five things for pharma marketers to know: Wednesday, March 22, 2017
- Five things for pharma marketers to know: Monday, March 20, 2017
- Novartis aims to bring first oral asthma drug to market in two decades
- Five things for pharma marketers to know: Tuesday, March 21, 2017
- Five things for pharma marketers to know: Friday, March 17, 2017
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Publicis Health formalizes new name, promotes 3 execs
- Digital IDs become focus as drugmakers seek to track doctors' behavior online